SensoLyte® 520 Insulin Degrading Enzyme (IDE) Activity Assay - Industry's First
SensoLyte Insulin Degrading Enzyme Assay Kit

SensoLyte®520 IDE Activity Assay Kit (Cat# AS-72231)

Line
Industry's first enzymatic assay for detection of IDE activity
Line
✓ Sensitive - assay detects as low as 0.8 ng/mL active IDE
Line
✓ Long wavelength, green fluorimetric assay kit (Ex/Em=490/520 nm) –     minimal autofluorescence
Line
✓ Fluorescence signal proportional to enzyme activity
Line
✓ Convenient homogeneous assay, 96-well format
Line
✓ Assay can be completed in as short as 1h
Line
✓ Unique substrate - minimal cross reactivity with Neprilysin, ADAM10,
    TACE, BACE-1 & -2
Line
✓ Test samples can be from biological sources or purified enzyme     preparations
Line
✓ Adaptable to high throughput screening (HTS)
Line
IDE FRET
Figure 1.Upon recognition and cleavage of FRET substrate (in SensoLyte® 520 IDE assay) by IDE, the quenched fluorescence is released and measured. Fluorescence signal is proportional to IDE activity.
IDE Inhibitor curve
Figure 2. Inhibition of IDE activity by 1, 10-Phenanthroline as measured with SensoLyte® 520 IDE Activity Assay Kit.

 

Product Catalog #

SensoLyte® 520 IDE Activity Assay Kit *Fluorimetric* NEW

AS-72231

AnaSpec is pleased to release the first commercially available FRET-based assay kit for the measurement of Insulin Degrading Enzyme (IDE) activity - the SensoLyte ® IDE Activity Assay Kit.

 

Insulin degrading enzyme (IDE), an extremely conserved Zn2+ metalloendopeptidase, belongs to the M16A metallopeptidase family.1-3 IDE is expressed in almost all tissues and distributed in the cytosol. IDE degrades various substrates such as insulin, IGF-II, TGF-α, glucagon, amylin, calcitonin, β-amyloid and amyloid precursor protein (APP); hence, IDE is considered a physiological and pathological relevant enzyme.4-6 Growing evidences have indicated that IDE may be involved in the pathogenesis of Alzheimer's disease and diabetes mellitus type 2.2, 7, 8 A paper published in the May 21st (2014) issue of Nature reported that an IDE inhibitor increases insulin and leads to higher glucose tolerance, thus making IDE a potentially new target for the treatment of diabetes.9

RELATED PRODUCTS:

ß-Amyloid Peptides - Wide Collection
Anti-ß-Amyloid Antibodies - monoclonal and polyclonal antibodies
SensoLyte® Assay Kits for Alzheimer's and Parkinson's Disease Research
SensoLyte®Amyloid Degrading Protease Assay Kits
Tau Products - Antibodies, Recombinant Proteins and Peptides


References
1. Fernández-Gamba, A. et al. Curr Pharm Des 15, 3644 (2009).
2. McCord, LA. et al. Proc Natl Acad Sci USA 110, 13827 (2013).
3. de Tullio, MB. et al. Prion 2, 51 (2008).
4. Edbauer, D. et al. J Biol Chem 277, 13389 (2002).
5. Morelli, L. et al. Biochem Biophys Res Commun 332, 808 (2005).
6. Kurochkin, IV. Trends Biochem Sci 26, 421 (2001).
7. Delledonne, A. et al. Mol Neurodegener 4, 39 (2009).
8. Zhao, J. et al. Mol Neurodegener 4, 4 (2009).
9. Maianti, JP. et al. Nature (2014). doi:10.1038/nature13297.